Lyell Immunopharma, Inc. beat EPS estimates 100% of the time across 1 reported quarters (1 beats, 0 misses), averaging +1.0% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-1.94 | $-1.92 | +1.0% | Beat | |
| Q1 FY26 | not reported | $-1.10 | not reported | not reported | |
| Q4 FY25 | not reported | $-7.68 | not reported | not reported |
Back to LYEL overview · LYEL holders · LYEL KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.